Humanity is aspiring to transcend old age and death. In the 21st century, this might no longer be an unattainable dream.
With everyday exposure to news media, movies, novels and theater, it is easy to assume that artificial intelligence (AI) will be able to provide all-powerful machinery capable of solving matters such as birth, aging, sickness or death — but how far has AI actually progressed in terms of medical science?
As top medical journals show, the progress made by AI goes no further than the ability to more meticulously analyze retinal changes as a result of diabetes in angiographic images; more precisely identify melanoma in dermoscopy images; find lymph node metastasis through analyzing histopathology images of breast cancer patients more accurately and faster than pathologists; forecast blood sugar levels by making calculations based on human genes and gastrointestinal microbiota; and assist oncologists’ decisionmaking by providing more informed and concise suggestions for cancer treatment, an AI technology provided by IBM’s Watson for Oncology.
The IBM Watson after its launch in 2016 received polarized opinions following its failure at the University of Texas’ MD Anderson Cancer Center, with some considering its AI capacity to be immature.
However, the higher the expectations, the greater the disappointment when the technology fails.
Just like the aforementioned advanced medical applications for AI technology, the IBM Watson for Oncology is by no means all-encompassing. It was not designed to diagnose cancers, but to target seven kinds of cancer and provide more in-depth and specific treatment advice. It also cannot give advice on surgery and radiation therapy, nor can it offer suggestions to patients with cancer recurrence or metastasis.
It might sound as if the IBM Watson is useless and not nearly as miraculous as the public believes it to be, but when it comes to treating people diagnosed with early stages of one of the seven targeted kinds of cancer, it provides detailed suggestions for medication and treatment, including chemotherapy, targeted therapy and immunotherapy.
Its suggestions are not only in accordance with the therapy already under way, but it also offers new directions and, in some cases, therapeutic opinions.
Within the scope of its database, IBM Watson is knowledgeable and it keeps “studying” new findings from journals to enhance the precision and subtlety of its analyses.
If the question is whether AI technology can replace an outstanding oncologist, the answer is “of course not.” However, if the question is changed to “Will AI under certain circumstances be able to assist oncologists by providing more precise therapeutic opinions for cancer patients?” then the answer is probably “yes.”
Every time a new technology emerges, public expectations rise too high on the assumption that it will solve all current difficulties. In particular, people find it hard to resist imaginative temptation when it comes to a sexy phrase such as “artificial intelligence.” These wild fantasies often lead to what is known as “technology hype.”
In terms of AI applications in medicine, moderate technology hype could encourage entrepreneurs to make venture investments and bring new capital into the field, thus encouraging the world’s top 10 companies to put a large amount of funds and talent into research. After all, finding the solution to issues related to birth, aging, sickness and death is humankind’s Holy Grail and a tremendously huge business that is growing 10 percent annually.
However, generating too much hype might lead to disappointments and the end of investment and research.
To AI researchers, this scenario sounds all too familiar. Since its emergence, AI has experienced at least two cold spells, both of which began when the technology was over-hyped and bestowed with too many unattainable goals. The Fifth-Generation Computer Systems initiated by Japan, for instance, disappeared quietly into thin air.
The question is whether there will be a third “cold spell” following the most recent emergence. Nevertheless, this possibility looks slim, as the causes of the two previous cold spells have been thoroughly analyzed and their lessons have been learned.
If concise development goals can be established, more rational expectations kept and an early harvest list for specific fields set up beforehand, current hardware processing speed and software maturity mean that the risk for a third cold spell is not great.
In other words, the public might finally be able to enjoy the fruits of AI technology.
Jack Li is dean of Taipei Medical University’s College of Medical Science and founder of the Center for Artificial Intelligence for Medical and Health Innovation.
Translated by Chang Ho-ming
Saudi Arabian largesse is flooding Egypt’s cultural scene, but the reception is mixed. Some welcome new “cooperation” between two regional powerhouses, while others fear a hostile takeover by Riyadh. In Cairo, historically the cultural capital of the Arab world, Egyptian Minister of Culture Nevine al-Kilany recently hosted Saudi Arabian General Entertainment Authority chairman Turki al-Sheikh. The deep-pocketed al-Sheikh has emerged as a Medici-like patron for Egypt’s cultural elite, courted by Cairo’s top talent to produce a slew of forthcoming films. A new three-way agreement between al-Sheikh, Kilany and United Media Services — a multi-media conglomerate linked to state intelligence that owns much of
The US and other countries should take concrete steps to confront the threats from Beijing to avoid war, US Representative Mario Diaz-Balart said in an interview with Voice of America on March 13. The US should use “every diplomatic economic tool at our disposal to treat China as what it is... to avoid war,” Diaz-Balart said. Giving an example of what the US could do, he said that it has to be more aggressive in its military sales to Taiwan. Actions by cross-party US lawmakers in the past few years such as meeting with Taiwanese officials in Washington and Taipei, and
The Republic of China (ROC) on Taiwan has no official diplomatic allies in the EU. With the exception of the Vatican, it has no official allies in Europe at all. This does not prevent the ROC — Taiwan — from having close relations with EU member states and other European countries. The exact nature of the relationship does bear revisiting, if only to clarify what is a very complicated and sensitive idea, the details of which leave considerable room for misunderstanding, misrepresentation and disagreement. Only this week, President Tsai Ing-wen (蔡英文) received members of the European Parliament’s Delegation for Relations
Denmark’s “one China” policy more and more resembles Beijing’s “one China” principle. At least, this is how things appear. In recent interactions with the Danish state, such as applying for residency permits, a Taiwanese’s nationality would be listed as “China.” That designation occurs for a Taiwanese student coming to Denmark or a Danish citizen arriving in Denmark with, for example, their Taiwanese partner. Details of this were published on Sunday in an article in the Danish daily Berlingske written by Alexander Sjoberg and Tobias Reinwald. The pretext for this new practice is that Denmark does not recognize Taiwan as a state under